SMARCA4 and neoplasm: In view of all these reported cases, there is a high possibility that ICI therapy can be considered as a treatment option for SMARCA4-deficient tumors with or without a PD-L1 IHC response by efficiently reducing tumor burden both clinically and symptomatically.